Market Overview

UPDATE: JMP Securities Initiates Coverage On Parnell Pharmaceuticals On Compelling Investment Opportunity


In a report published Monday, JMP Securities analyst J.T. Haresco initiated coverage on Parnell Pharmaceuticals Holdings Ltd. (NASDAQ: PARN) with a Market Outperform rating and $12.00 price target.

In the report, JMP Securities noted, “Parnell is a fully integrated pharmaceutical company headquartered in Australia, focused on developing, manufacturing, and commercializing innovative animal health solutions. The company currently has five products marketed in 14 countries. On 6/18/14, Parnell completed its IPO, issuing 5.0M shares of common stock at $10.00/share, resulting in net proceeds of $50M.

"We believe the company offers a compelling investment opportunity because: 1) it is poised to benefit from the attractive growth of the pet industry; 2) ZYDAX®, a disease-modifying osteoarthritis drug, does not have a direct competitor; 3) Parnell's lead reproductive products, estroPLAN and GONAbreed were the first hormones to be FDA approved for estrous synchronization in dairy cows; 4) Parnell introduces a novel commercial model by combining therapeutics with a service-oriented strategy for disease and herd management; 5) the company's strategy carries less regulatory and commercial risk than human therapeutic development; 6) the company has a pipeline of unique products that targets unmet needs in the pet and large animal health market; and 7) the management team has substantial experience in the field of companion and large animal therapeutic development.”

Parnell Pharmaceuticals Holdings Ltd. closed on Friday at $6.85.

Latest Ratings for PARN

Apr 2016JefferiesMaintainsBuy
Aug 2015PiperJaffrayMaintainsOverweight
Jul 2014PiperJaffrayInitiates Coverage onOverweight

View More Analyst Ratings for PARN
View the Latest Analyst Ratings

Posted-In: J.T. Haresco JMP SecuritiesAnalyst Color Initiation Analyst Ratings


Related Articles (PARN)

View Comments and Join the Discussion!

Latest Ratings

PLXSSidoti & Co.Initiates Coverage On0.0
TIFBank of AmericaReiterates104.0
MOBank of AmericaReiterates66.0
FDXBank of AmericaReiterates188.0
AUPHRaymond JamesMaintains11.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Trader Essentials
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Benzinga's Top #PreMarket Gainers

UPDATE: Teva Announces FDA Acceptance of NDA For Inhaler